Skip to main content
OpenTrials
Completed

NCT Number: NCT03570814

Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin

Cluster-randomised trial comparing co-administration of Azithromycin/Ivermectin/Albendazole with separate administration of Azithromycin and Ivermectin/Albendazole.

The study will be conducted in Beneshangul-Gumuz region, Ethiopia. Within this district, a study group of 8,000 people (in approximately 40 clusters) will receive the azithromycin, ivermectin & albendazole at a single time. A control group of 8,000 people (in approximately 40 clusters) within the same district will receive the current MDA treatment schedule beginning with Ivermectin/Albendazole followed two weeks later with azithromycin. All drug dosing will be in line with standard FMOH and WHO Guidelines for MDA for trachoma and lymphatic filariasis.

The study will randomly sort subdistrict communities (Gotes) into the trial arm and the control arm. The study will compare the number of adverse events (AEs) and severe adverse events (SAEs) between the two arms to determine if co-administration is not inferior to the standard treatment. The primary outcome will be to demonstrate the safety of the triple-drug administration as measured by incidence of AEs/SAEs following the MDA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Trachoma Bacterial Infections Bacterial Infections and Mycoses Chlamydia Infections Chlamydiaceae Infections Conjunctival Diseases Conjunctivitis Conjunctivitis, Bacterial Corneal Diseases Elephantiasis, Filarial Eye Diseases Eye Infections Eye Infections, Bacterial Filariasis Gram-Negative Bacterial Infections Helminthiasis Hemic and Lymphatic Diseases Infections Lymphatic Diseases Lymphatic Filariases Lymphedema Mosquito-Borne Diseases Nematode Infections Parasitic Diseases Secernentea Infections Spirurida Infections Vector Borne Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Community Recruitment across whole district

Community Recruitment Across Whole District, Ethiopia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Residing in the community for at least three months;
  • Eligible to receive all three agents according to standard MDA criteria

Exclusion criteria

  • Not eligible to receive one or more drugs according to standard MDA criteria;
  • Less than 5 years of age (not eligible for ivermectin)**
  • Pregnant women (azithromycin only, not eligible for albendazole and ivermectin)
  • Lactating women (Only administered azithromycin and albendazole, not eligible for ivermectin)**
  • History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole)
  • Residents who cannot swallow tablets
  • Note that patients that are not eligible for IVM, will receive azithromycin and albendazole. Patients that receive azithromycin and albendazole will be followed up through the same procedure as the triple drug therapy to try to track any AEs attributed to the two drug combination.

Treatment and study plan

Administration of Albendazole on Day 1

Drug

Participants will receive Albendazole 400mg on study day 1.

Administration of Ivermectin on Day 1

Drug

Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.

Administration of Azithromycin on Day 1

Drug

Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.

Administration of Azithromycin on Day 15

Drug

Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.

Primary outcomes

  1. Self Reported Adverse Event

    Time frame: 1 Month

    The incidence of self-reported adverse events following MDA. We will collect data on the presence of common symptoms/signs prior to drug administration. All patients will be reviewed 24-48 hours after treatment and asked to report adverse events. We will calculate the proportion of newly occurring adverse events following treatment and calculate the whether the proportion of patients experiencing an adverse event differs between study arms,

Secondary outcomes

  1. Cost of Administration Drug Separately compared to Cost of Co-Administration of Drugs

    Time frame: 1 month

    Analysis of the cost effectiveness of co-administration compared to separate administration of drugs

  2. Community perceptions

    Time frame: 1 month

    An analysis of community perceptions of benefits of co-administration at a single time point vs standard separated MDA will be conducted by conducting focus groups and in-depth interviews with study participants.

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Collaborators

  • Armauer Hansen Research Institute, Ethiopia
  • Federal Minstry of Health of Ethiopia

Registry information

Official study title

Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jun 27, 2018
Registry last updated
Aug 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.